Hawley blasts FDA approval of new abortion drug, cites safety and trust concerns

Senator Josh Hawley has criticized the FDA's recent approval of generic mifepristone from Evita Solutions, expressing concerns about safety and the agency's regulatory practices. This approval is significant as it impacts access to abortion medication, and Hawley's remarks highlight ongoing debates about women's health and trust in regulatory bodies. His stance reflects broader political tensions surrounding reproductive rights and the implications for healthcare policies.